World
Biocon’s Pebrilzo becomes first biosimilar approved under EMA’s tailored clinical pathway
The approval marks a regulatory milestone for Biocon and expands its portfolio of oncology biosimilars approved in Europe and the United States.
BU
Originally published byBusiness Line - Home 27m ago · thehindubusinessline.com
NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.
